Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731094 | 0.80 | LMNA (0.57) | ARLMNATAS2R14 | |
| SCHEMBL202481 | 0.80 | LMNA (0.57) | ARLMNATAS2R14 | |
| SCHEMBL13216335 | 0.80 | LMNA (0.57) | ARLMNATAS2R14 | |
| SCHEMBL30158523 | 0.80 | LMNA (0.57) | ARLMNATAS2R14 | |
| SCHEMBL202340 | 0.79 | AR (0.51) | ARRXRARXRBRXRGTAS2R14 | |
| SCHEMBL203574 | 0.79 | AR (0.45) | AR | |
| SCHEMBL6819872 | 0.73 | LMNA (0.52) | LMNA | |
| SCHEMBL20637747 | 0.73 | AR (0.64) | AR | |
| SCHEMBL20637748 | 0.73 | AR (0.64) | AR | |
| SCHEMBL29504172 | 0.73 | AR (0.64) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2020243373-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885LMNA 579/4885RXRA 1457/4885 |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885LMNA 579/4885RXRA 1457/4885 |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885LMNA 579/4885RXRA 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.